MX2024004213A - Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. - Google Patents

Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.

Info

Publication number
MX2024004213A
MX2024004213A MX2024004213A MX2024004213A MX2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A MX 2024004213 A MX2024004213 A MX 2024004213A
Authority
MX
Mexico
Prior art keywords
inhibitors
kras
pi3ka
combinations
treatment
Prior art date
Application number
MX2024004213A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Peter Olson
Jill Hallin
Vickie Bowcut
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024004213A publication Critical patent/MX2024004213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004213A 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. MX2024004213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252384P 2021-10-05 2021-10-05
PCT/US2022/045619 WO2023059594A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment

Publications (1)

Publication Number Publication Date
MX2024004213A true MX2024004213A (es) 2024-07-29

Family

ID=85803703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004213A MX2024004213A (es) 2021-10-05 2022-10-04 Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados.

Country Status (10)

Country Link
US (1) US20240408098A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412716A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537139A (cg-RX-API-DMAC7.html)
KR (1) KR20240073112A (cg-RX-API-DMAC7.html)
CN (1) CN118338904A (cg-RX-API-DMAC7.html)
AU (1) AU2022359282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233566A1 (cg-RX-API-DMAC7.html)
IL (1) IL311834A (cg-RX-API-DMAC7.html)
MX (1) MX2024004213A (cg-RX-API-DMAC7.html)
WO (1) WO2023059594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250120981A1 (en) * 2023-10-12 2025-04-17 Mirati Therapeutics, Inc. Mrtx1133 pharmaceutical compositions
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
ES2738864T3 (es) 2013-03-12 2020-01-27 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS
AU2019355574A1 (en) 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof

Also Published As

Publication number Publication date
US20240408098A1 (en) 2024-12-12
EP4412716A1 (en) 2024-08-14
IL311834A (en) 2024-05-01
EP4412716A4 (en) 2025-08-13
AU2022359282A1 (en) 2024-04-11
WO2023059594A1 (en) 2023-04-13
KR20240073112A (ko) 2024-05-24
JP2024537139A (ja) 2024-10-10
CA3233566A1 (en) 2023-04-13
CN118338904A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
MX2024009727A (es) Terapias de combinacion.
MX2024004214A (es) Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados.
MX2024012131A (es) Composicion farmaceutica, uso de la misma y metodo para tratar el cancer
EA202190749A1 (ru) Способы комбинированной терапии
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2023002248A (es) Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2024004216A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12022553501A1 (en) Alk2 inhibitors for the treatment of anemia
ZA202304965B (en) Combination therapy for treating cancer
MX2025013118A (es) Tratamiento combinado para una enfermedad o un trastorno relacionado con ras
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2024006678A (es) Inhibidor de cdk4 para el tratamiento del cancer.
AU2018271862A1 (en) Combination therapy